DALLAS, July 30, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring pharmaceutical company Ariad Pharmaceuticals Inc. (Nasdaq:ARIA). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Ariad Pharmaceuticals Inc. (ARIA) should be of particular interest to other pharmaceutical companies: Novartis AG (NYSE:NVS), Wyeth (NYSE:WYE), Amgen Inc. (Nasdaq:AMGN) and Genzyme Corp. (Nasdaq:GENZ).
It is available at: http://www.beaconequity.com/i/ARIA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
ARIA is an emerging pharmaceutical company focused on the development and commercialization of novel drugs for the treatment of various types of cancer. Its lead drug candidate deforolimus is in phase III trials for the treatment of solid tumors. The Company's AP24534 is in phase I clinical trials for the treatment of chronic myeloid leukemia and other hematological cancers.
In the report, the analyst notes:
"Following rapid growth rates from 2004 to 2008, drug sales of respiratory related conditions is expected to reach $23 billion by 2018, according to The Datamonitor Group, while the most recent statistics for the global market potential of the Company's deforolimus and AP24534 anti-cancer drug therapy could reach approximately $53 billion for 2009.
"If approved by the U.S. Food and Drug Administration (FDA), the market for the Company's lead drug candidate deforolimus could reach more than $1 billion at its market saturation. Deforolimus is in phase III clinical trials, with the prospects of commercialization reaching approximately 90% following its clearance of phase III trials."
To read the entire report visit: http://www.beaconequity.com/i/ARIA
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.